Adagio Medical Announces Initiation and First Procedure in FULCRUM-VT Trial, Starting The Process For Bringing Ultra-Low Temperature Cryoablation for Ventricular Arrhythmias to US Market

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Adagio-Medical

More Like This

PR Newswire associated0

Adagio Medical Announces CE Mark approval of VT Cryoablation System, Plans for Immediate Commercialization in Select European Centers

PR Newswire associated0

Circulation Publishes 6-Month Outcomes from First-in-Human VCAS Trial of FieldForce™ Pulsed Field Ablation System: 82% Freedom from VT/VF Recurrence and 98% Reduction in Burden

PR Newswire associated0

Field Medical First-in-Human 6-Month Data Selected for Late-Breaking Clinical Trial at VT Symposium 2025

Imricor VISABL-VT Clinical Trial Enrollment

Imricor Commences VISABL-VT Trial

PR Newswire associated0

Adagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation Technologies

PR Newswire associated0

Field Medical Announces First-in-Human Trials for Groundbreaking FieldForce™ Ventricular Pulsed Field Ablation Technology

Business Wire logo

MedLumics New CEO and Board Member Announces 10 Patients Treated in First in Man (FIM) Clinical Trial With the Real-Time Visually Guided AblaView PFA System

PR Newswire associated0

FIELD MEDICAL CLOSES $40 MILLION SERIES A FINANCING TO REDEFINE PULSED FIELD ABLATION FOR VENTRICULAR TACHYCARDIA